OBIO vs CRBP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OBIO Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Momentum & Technical, Options & Structure while CRBP counters with relative strength in Growth & Margin. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus CRBP at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | CRBP Revenue | OBIO Op. Margin | CRBP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1176.8% | CRBP |
| FY2019 | N/A | $40M | N/A | -213.3% | CRBP |
| FY2020 | N/A | $0M | N/A | -3119.2% | CRBP |
| FY2021 | N/A | $0M | N/A | -6350.1% | CRBP |
| FY2022 | $0M | N/A | -924.3% | N/A | OBIO |
| FY2023 | $0M | N/A | -1866.2% | N/A | OBIO |
| FY2024 | $0M | N/A | -2437.5% | N/A | OBIO |
| FY2025 | $30M | N/A | -154.7% | N/A | OBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | CRBP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $570.6M | $69.9M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -89.4% | -100.0% | Higher Growth | OBIO |
| Operating Margin (TTM) Profitability | -195.4% | 0.0% | Higher Margin | CRBP |
| Net Profit Margin Profitability | -182.5% | 0.0% | Higher Margin | CRBP |
| Return on Equity (ROE) Capital Efficiency | -182.3% | -131.5% | Higher ROE | CRBP |
| 52-Week Range Position Momentum | 92% ($3โ$7) | 6% ($3โ$13) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.15ฮฒ ยท 82% Vol | 1.93ฮฒ ยท 121% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 37.5 / 100 (SELL) | 42.5 / 100 (HOLD) | Higher Composite | CRBP |